Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

ClinicalTrials.gov ID: NCT02567656

Public ClinicalTrials.gov record NCT02567656. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Study identification

NCT ID: NCT02567656
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Rhizen Pharmaceuticals SA; Industry
Enrollment: 58 participants

Conditions and interventions

Conditions

Interventions

RP6530 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2015
Primary completion: Feb 28, 2018
Completion: Dec 9, 2018
Last update posted: Jan 12, 2020

2015 – 2018

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	—
Chao Family Comprehensive Cancer Center University of California Irvine	Orange	California	92868	—
University of Colorado Cancer Center	Aurora	Colorado	80045	—
Emory University School of Medicine	Atlanta	Georgia	30322	—
University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	48109-0944	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106-5028	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02567656, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 12, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02567656 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →